1. Clinical & Scientific Overview
Timolol Maleate Ophthalmic (0.5% Glaucoma Beta-Blocker Drops) (TIP-MED-000252, Reference Code [12.20]) is classified under
Ophthalmological & Otic (ENT) Preparations (Ch 12) as a Non-Selective Beta-1 / Beta-2 Adrenergic Antagonist Ophthalmic Solution (Aqueous Humour Suppressant).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.20], p. 164): Iopar, Glucomol, Timolet, Ocudor — Strengths & Dosage Forms: Ophthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.
Ophthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.
3. Mechanism of Action & Pharmacodynamics
Blocks beta-2 adrenergic receptors on the non-pigmented ciliary epithelium -> decreases aqueous humour production by 30-50% -> lowers intraocular pressure (IOP) without affecting pupil size or accommodation.
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic open-angle glaucoma
- ocular hypertension
- secondary glaucoma
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: 1 drop of 0.25% or 0.5% solution into affected eye(s) twice daily (q12h); Gel-Forming Solution: 1 drop once daily in the morning. • Paediatric: Congenital/Paediatric Glaucoma: 0.25% 1 drop BD under specialist supervision (punctal occlusion mandatory).
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.
Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.
Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Bronchial asthma or history of asthma, severe COPD, sinus bradycardia (<50 bpm), 2nd- or 3rd-degree AV block, overt cardiac failure, cardiogenic shock. • Precautions: CRITICAL SYSTEMIC ABSORPTION HAZARD: Eye drops draining through the nasolacrimal duct into the nasal mucosa bypass hepatic first-pass metabolism—1 drop of 0.5% Timolol in each eye delivers systemic beta-blockade equivalent to a 10 mg oral dose and can trigger fatal bronchospasm in asthmatics or complete heart block in the elderly!
Key Clinical Precautions: Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.
8. Adverse Effects Profile
- Transient ocular burning/stinging, dry eyes, blurred vision (gel).
- Severe bronchospasm/status asthmaticus, sinus bradycardia, syncope, heart block, masking of hypoglycaemia in insulin-treated diabetics.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Oral Beta-blockers (Metoprolol, Bisoprolol), Verapamil, Diltiazem, Digoxin, Amiodarone -> additive severe bradycardia, AV block, and hypotension; Inhalational Beta-2 agonists (Salbutamol) -> antagonises bronchodilation
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: MANDATORY NASOLACRIMAL OCCLUSION TECHNIQUE: After instilling 1 drop, close eyelids gently and press index finger firmly over the inner corner of the eye (tear duct next to nose) for 2 full minutes—this cuts systemic bloodstream absorption by >65% and improves eye efficacy; wait >=5 minutes between different eye drops.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ophthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.20] (p. 164)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.22] Carboxymethylcellulose Sodium (0.5% / 1% Lubricant Eye Drops) — Cellulose Polymer Ocular Lubricant / Artificial Tears (Viscoelast
- [12.30] Otic Ciprofloxacin, Clotrimazole & Cerumenolytic Ear Drops — Topical Otic Fluoroquinolone, Imidazole Antifungal, Corticosteroi
- [12.5]-C150 Brimonidine Tartrate — Topical Ophthalmic Beta-Blockers (Timolol), Prostaglandin Analogu
- [12.5]-C151 Dorzolamide / Moxifloxacin Ophthalmic Drops — Topical Ophthalmic Beta-Blockers (Timolol), Prostaglandin Analogu